Why AstraZeneca Is Betting Big on America

AstraZeneca has unveiled a sweeping $50 billion investment plan to expand its operations in the United States by 2030, marking one of the largest pharmaceutical commitments to the country.

The move comes amid rising pressure from the Trump administration, which has threatened new tariffs on imported medicines and called for drugmakers to prioritize domestic production.

The investment will fund a new manufacturing facility in Virginia and bolster research, clinical trials, and cell therapy work in states like Maryland, Texas, and California.

More than 40% of AstraZeneca’s revenue already comes from the U.S., and the company now aims to make the U.S. its largest production hub, with half its global earnings projected to come from the American market by 2030.

The announcement coincides with a U.S. Department of Commerce investigation into pharmaceutical imports, signaling that companies may soon face stricter trade conditions.

The move builds on a previous $3.5 billion U.S. investment and reflects how the global pharmaceutical industry is shifting strategies in response to growing protectionist policies.